Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT04161014
Registration number
NCT04161014
Ethics application status
Date submitted
7/11/2019
Date registered
13/11/2019
Titles & IDs
Public title
The Nintedanib in Progressive Pneumoconiosis Study (NiPPS): a Collaborative NSW Treatment Trial
Query!
Scientific title
The Nintedanib in Progressive Pneumoconiosis Study (NiPPS): a Collaborative NSW Treatment Trial
Query!
Secondary ID [1]
0
0
NiPPs
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
NiPPs
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Pneumoconiosis Coal
0
0
Query!
Asbestosis
0
0
Query!
Silicosis
0
0
Query!
Condition category
Condition code
Respiratory
0
0
0
0
Query!
Other respiratory disorders / diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Nintedanib 150 MG [Ofev]
Other: Treatment Arm - Nintedanib 150mg twice daily for 3 years
Treatment: Drugs: Nintedanib 150 MG [Ofev]
Nintedanib 150mg twice daily for 3 years
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
annual decline in FVC
Query!
Assessment method [1]
0
0
measured in millilitres per year, calculated from serial measurements
Query!
Timepoint [1]
0
0
36 months
Query!
Secondary outcome [1]
0
0
K-BILD score
Query!
Assessment method [1]
0
0
Absolute change from baseline in King's Brief Interstitial Lung Disease Questionnaire (K-BILD) total score. The KBILD domain and total score ranges are 0-100; 100 represents best health status
Query!
Timepoint [1]
0
0
week 52
Query!
Secondary outcome [2]
0
0
Time to acute exacerbation
Query!
Assessment method [2]
0
0
an acute, clinically significant respiratory deterioration characterized by evidence of new, widespread alveolar abnormality, including unexplained worsening or development of dyspnea,new diffuse pulmonary infiltrates visualized on chest radiography, HRCT, or both, or the development of parenchymal abnormalities with no pneumothorax or pleural effusion (new ground-glass opacities) since the preceding visit; and exclusion of any known causes of acute worsening, including infection, left heart failure, pulmonary embolism, and any identifiable cause of acute lung injury, in accordance with routine clinical practice and microbiologic studies.
Query!
Timepoint [2]
0
0
36 months
Query!
Secondary outcome [3]
0
0
Time to referral for Lung transplantation
Query!
Assessment method [3]
0
0
Respiratory deterioration which necessitates a referral for lung transplant
Query!
Timepoint [3]
0
0
36 months
Query!
Secondary outcome [4]
0
0
Time to death
Query!
Assessment method [4]
0
0
Respiratory deterioration leading to death
Query!
Timepoint [4]
0
0
12, 24 and 36 months
Query!
Eligibility
Key inclusion criteria
* Pneumoconiosis diagnosis confirmed at the Occupational MDT (Occ-MDT)
* diffuse fibrosing lung disease of extent >10% on HRCT with protocol criteria for progression
* Asbestosis, silicosis, coal worker's pneumoconiosis and diffuse dust fibrosis
* FVC =45% predicted and TLCO above 30% predicted
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* idiopathic pulmonary fibrosis (IPF) and non-occupational progressive pulmonary fibrosis
* ILD due to connective tissues disorders, hypersensitivity pneumonitis, non-occupational interstitial pneumonia, non-occupational sarcoidosis
* contraindications to Nintedanib (forthcoming surgery, use of anticoagulants, high CVD risk, liver function abnormalities)
Query!
Study design
Purpose of the study
Other
Query!
Allocation to intervention
NA
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
9/10/2020
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/02/2025
Query!
Actual
Query!
Sample size
Target
100
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW
Query!
Recruitment hospital [1]
0
0
Holdsworth House Medical Practice - Sydney
Query!
Recruitment postcode(s) [1]
0
0
2010 - Sydney
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
Holdsworth House Medical Practice
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/industry
Query!
Name [1]
0
0
Boehringer Ingelheim
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Prospective clinical pilot study for subjects diagnosed with Occupational Progressive Pneumoconiosis. Subjects will be treated with Nintedanib 150mg twice daily for 3 years.
Query!
Trial website
https://clinicaltrials.gov/study/NCT04161014
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Deborah Yates, A/Prof
Query!
Address
0
0
Holdsworth House Medical Practice
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Trina Vincent, RN
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
0280381044
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT04161014